Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
NASDAQ:PTCT
PTCT Stock Chart & Stats
$77.59
>-$0.01(-0.02%)
At close: 4:00 PM EST
$77.59
>-$0.01(-0.02%)
Day’s Range― - ―
52-Week Range$35.95 - $87.50
Previous CloseN/A
Volume146.45K
Average Volume (3M)1.28M
Market Cap
$6.22B
Enterprise Value$4.07B
Total Cash (Recent Filing)$1.71B
Total Debt (Recent Filing)$2.49B
Price to Earnings (P/E)9.1
Beta1.17
Next Earnings
Feb 24, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.20
Shares Outstanding80,288,310
10 Day Avg. Volume1,159,001
30 Day Avg. Volume1,278,293
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)-3.16
Price to Sales (P/S)4.30
P/FCF Ratio-30.38
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue2.29
Enterprise Value/Gross Profit2.51
Enterprise Value/Ebitda4.46
Forecast
1Y Price Target
$78.18Price Target Upside0.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline Depth And Balance SheetA diversified pipeline that includes vatiquinone and translarna, together with a strong cash position, provides multiple potential revenue drivers and financial flexibility to advance development programs.
Regulatory ProgressRegulatory alignment on the votoplam Phase III trial design in Huntington's disease could support a pathway to accelerated approval if selected endpoints demonstrate clinically meaningful benefit.
Sephience LaunchStrong early Sephience uptake across prescribers and patients indicates material room for market penetration if commercial execution sustains and treatment starts expand.
Bears Say
DMD Franchise WeaknessContinued weakness in the DMD franchise and product erosion could offset gains from new launches and pressure overall revenue growth.
Partnership And Revenue VariabilityDependence on partner-derived revenues and potential volatility in collaboration receipts could contribute to uneven results and downside to revenue expectations.
Patient Persistence And Efficacy UncertaintyLingering uncertainty about long-term patient persistence and expected phenylalanine reductions may restrain adoption forecasts and increase payer scrutiny.
PTC Therapeutics News
PTCT FAQ
What was PTC Therapeutics’s price range in the past 12 months?
PTC Therapeutics lowest stock price was $35.95 and its highest was $87.50 in the past 12 months.
What is PTC Therapeutics’s market cap?
PTC Therapeutics’s market cap is $6.22B.
When is PTC Therapeutics’s upcoming earnings report date?
PTC Therapeutics’s upcoming earnings report date is Feb 24, 2026 which is in 41 days.
How were PTC Therapeutics’s earnings last quarter?
PTC Therapeutics released its earnings results on Nov 04, 2025. The company reported $0.2 earnings per share for the quarter, beating the consensus estimate of -$1.133 by $1.333.
Is PTC Therapeutics overvalued?
According to Wall Street analysts PTC Therapeutics’s price is currently Undervalued.
Does PTC Therapeutics pay dividends?
PTC Therapeutics does not currently pay dividends.
What is PTC Therapeutics’s EPS estimate?
PTC Therapeutics’s EPS estimate is -0.26.
How many shares outstanding does PTC Therapeutics have?
PTC Therapeutics has 80,288,310 shares outstanding.
What happened to PTC Therapeutics’s price movement after its last earnings report?
PTC Therapeutics reported an EPS of $0.2 in its last earnings report, beating expectations of -$1.133. Following the earnings report the stock price went up 5.981%.
Which hedge fund is a major shareholder of PTC Therapeutics?
Currently, no hedge funds are holding shares in PTCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PTC Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$78.18 (0.76% Upside)
$78.18 (0.76% Upside)
Blogger Sentiment
Bullish
PTCT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 147.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 9.5%
Last 30 Days ▲ 9.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
76.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
43.50%
Trailing 12-Months
Company Description
PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
PTCT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a strong positive sentiment driven by the successful initial launch of Sephience and the company's financial position. However, challenges with government payer policy finalizations and the uncertainty around Emflaza's future revenue potential were noted.View all PTCT earnings summariesPTCT Stock 12 Month Forecast
Average Price Target
$78.18
▲(0.76% Upside)
Technical Analysis
Ownership Overview
1.37% Insiders
25.11% Mutual Funds
27.61% Other Institutional Investors
18.03% Public Companies and
Individual Investors